Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry  

作　　者：Shulong Zu Dan Luo Lili Li Qing Ye Rui-Tinq Li Yanan Wang Meilinq Gao Heng Yang Yong-Qiang Deng Genhong Cheng 

机构地区：[1]Center for Systems Medicine,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [2]Institute of Systems Medicine,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [3]Suzhou Institute of Systems Medicine,Suzhou,Jiangsu,China [4]State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China [5]Suzhou Func Biotech Inc,Suzhou,Jiangsu,China [6]Department of Microbiology,Immunology and Molecular Genetics,University of California,Los Angeles,CA,USA

出　　处：《Signal Transduction and Targeted Therapy》2022年第1期34-37,共4页信号转导与靶向治疗（英文）

基　　金：This project is supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine(2021-I2M-1-047,2019-I2M-5-049 and 2016-I2M-1-005);Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(2020-PT310-006,2019XK310002,2018TX31001,and 3332018131);the National Natural Science Foundation of China(91542201,81925025,82102371,82174055,82073181,81802870,and 2017YFA0506200);the National Key Research and Development Project(2020YFC0841700);NIH R01AI069120,AI158154,and AI140718 grants,the UCLA AIDS Institute;UCLA David Geffen School of Medicine-Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program.H.Y.is supported by science funds from Jiangsu Province(BK20211554,BK20170407);the Innovative and Entrepreneurial Team grant(2018-2021)from Jiangsu Province.L.L.is supported by Innovative;Entrepreneurial Doctor grant(2020-2022)from Jiangsu Province.R.L.is supported by the Chinese Postdoctoral Science Foundation(2020T130135ZX).

摘　　要：Dear Editor,COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is still a threat to millions of lives worldwide.Although SARS-CoV-2 vaccines have been approved to reduce the severity and death associated with COVID-19,the number of SARS-CoV-2-infected cases still remains high,especially with the appearance of various mutant strains such as P.1.351 and P.1.617(also known as South Africa strain and India strain,respectively),which may reduce the efficacy of vaccine protection.There is an urgent need to develop effective antiviral agents to treat C0VID-19 patients,especially with those infected with SARS-CoV-2 variants of concern.

关 键 词：acute VACCINE RESPIRATORY 

分 类 号：R373[医药卫生—病原生物学]